Lannett Company (LCI) reported quarterly earnings results on Tuesday, Aug-23-2016. The company said it had a profit of $0.73 Earnings per Share for the quarter. The results exceeded Wall Street expectations beating the analyst consensus estimate by $0.13. Analysts had a consensus of $0.60. The company posted revenue of $168.90 million in the period, compared to analysts expectations of $161.56 million. The company’s revenue was up 70.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.91 EPS.
Many Wall Street Analysts have commented on Lannett Company. Deutsche Bank Initiated Lannett Company on Jun 29, 2016 to “Hold”, Price Target of the shares are set at $26.
Lannett Company opened for trading at $30.45 and hit $30.93 on the upside on Friday, eventually ending the session at $30.63, with a gain of 0.13% or 0.04 points. The heightened volatility saw the trading volume jump to 4,26,247 shares. Company has a market cap of $1,126 M.
In a different news, on Jul 6, 2016, Mahendra Dedhiya (Chief Scientific Affairs) purchased 1,000 shares at $24.84 per share price. According to the SEC, on Jun 24, 2016, Robert Ehlinger (VP and CIO) sold 37,141 shares at $25.07 per share price. On Feb 8, 2016, Albert Iii Paonessa (director) purchased 2,500 shares at $24.57 per share price, according to the Form-4 filing with the securities and exchange commission.
Lannett Company Inc. develops manufactures markets and distributes generic versions of brand pharmaceutical products. The Company’s products include Levothyroxine Sodium tablets Digoxin tablets Butalbital products Ursodiol capsules and pain management products. Levothyroxine Sodium tablets are produced and marketed with around 12 varying potencies. Digoxin tablets are produced and marketed with approximately two different potencies. It distributes around three products containing Butalbital. Ursodiol capsules are produced and marketed in 300 milligram capsules. The Company offers a range of pain management products such as Cocaine Topical Solution (C-Topical) Morphine Sulfate Oral Solution Hydromorphone hydrochloric acid (HCl) tablets and Codeine Sulfate tablets.